Background: Exosomes, via heat shock protein 70 (HSP70) expressed in their membrane, are able to interact with the tolllike receptor 2 (TLR2) on myeloid-derived suppressive cells (MDSCs), thereby activating them.
Exosome Purification
Cells were cultured in medium depleted from serum-derived exosomes. Supernatants were collected from cell lines and sequentially centrifuged at 300 xg for 10 minutes (4°C) and at 2000 xg for 10 minutes. Then, exosomes were ultracentrifugated at 100 000 xg for 70 minutes and washed in PBS. The same protocol was used for urine and blood samples. To evaluate exosome concentrations, we used a NanoSight LM10 instrument (NanoSight, Amesbury, UK).
Biolayer Interferometry
Protein-protein interaction experiments were conducted with an Octet Red instrument (FortéBio, Menlo Park, CA). The ligand (A8 or TLR2) was biotinylated using EZ-Link NHS-PEG 4 -biotin (2 nM, 30 min, RT, Thermo Fisher Scientific, Germany) and immobilized on streptavidin sensors (black 96-well plate, FortéBio). Further details are given in the Supplementary Methods (available online).
pSTAT3 Analysis
Myeloid suppressive cells 2 (MSC2) (2x10 6 ) or MDSCs (2x10 6 ) were incubated alone or with exosomes (from B16F10, CT26, HCT116, SW480) in the absence or presence of A8 or A17 (16 µM) for six hours (RPMI 10% FBS, 5% of CO 2 at 37°C). Every two hours, 5x10 6 cells were sampled and centrifugated five minutes at 300 xg. Cells were lysed in lysis buffer (50 mM HEPES [pH 7.6], 150 mM NaCl, 5 mM EDTA, and 0.1% NP40 and antiphosphatases, Roche). Then, pSTAT3 and STAT3 expression were analyzed by western blotting.
MDSC Cell Isolation and Analysis
Single-cell suspensions were prepared from spleens, and red cells were removed using ammonium chloride lysis buffer. Gr-1+ cells were isolated from spleens of different group of tumorbearing mice or naive mice by labeling the cells with PE-Cy7 Ab to Gr-1, then using magnetic PE-Cy7 beads and LS MACS columns (Miltenyi Biotec). For extracellular staining of immune markers, single-cell suspensions were prepared. We incubated 1x10 6 freshly prepared cells with fluorochrome-coupled CD11b antibody (eBioscience). All events were acquired by a BD Bioscience LSR-II device and analyzed with FlowJo (Tree Star).
Lymphocyte Isolation and Coculture Experiment
Single-cell suspensions were prepared from spleens, and red cells were removed using ammonium chloride lysis buffer.
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Lymphocytes were isolated from spleens of naive mice in a twostep procedure. Further details are given in the Supplementary Methods (available online).
Histologic Study of the Tumor
Mice were killed 15 or 18 days after cell injection. The site of tumor cell injection was resected and snap-frozen in liquid nitrogen. An immunohistochemical study of tumor-infiltrating inflammatory cells was performed on acetone-fixed 5 μm cryostat sections. Further details are given in the Supplementary Methods (available online).
MSC2 and MDSC Cell Proliferation Analysis
MSC2s' proliferation was analyzed by two different techniques. First, MSC2s (1x10 4 ) were seeded onto 16-well plates with medium containing 10% FBS and incubated for 34 hours. Then, cells were treated or not with exosomes (from B16F10) in the absence or presence of A8 (16 µM) for five days. Further details are given in the Supplementary Methods (available online).
Tumor Growth Analysis in Vivo
B16F10 cells (5x10 4 ) or EL4 (7x10 5 ) cells were injected s.c. into the right flank of C57BL/6 mice (Charles River, France) (n = 6 per group). Tumor volumes were evaluated every two days. Mice (n = 6 per group) were treated with a control peptide aptamer A0 (3 mg/kg) or aptamer A8 (3 mg/kg) and/or cisplatin (CDDP, 5 mg/ kg) or 5-fluorouracil (5FU, 25 mg/kg).
Statistical Methods
Quantitative results are expressed as means ± SD from at least three independent experiments. Quantitative data were compared using the Student's t test or Mann-Whitney according to their distribution. All statistical tests were twosided, and error bars in the graphs represent standard deviations. Graphics were analyzed using the GraphPad Prism program.
Results

HSP70 Peptide Aptamer A8 Can Be Used to Capture HSP70 Exosomes From Cancer Patient Samples
We previously showed that exosomes from mouse CT26 cancer cells expressed HSP70 on their membranes (HSP70 exosomes), which was responsible for MDSC activation (17) . Membranebound HSP70 presents an extracellular sequence composed of 14 amino acids in the C-terminal region, against which a monoclonal antibody was raised (cmHSP70) (26) . We previously described the selection of an 8-amino-acid peptide aptamer A8 (23) that binds within the peptide-binding domain of HSP70 (Supplementary Figure 1 , A and B, available online). To determine whether A8 could precisely associate to the extracellular sequence of membrane-bound HSP70 and therefore could be used to capture tumor-derived exosomes, we analyzed its ability to bind to extracellular HSP70 in the membrane of TDEs. Biolayer interferometry (BLI) showed that A8 efficiently captured exosomes and that it strongly decreased the ability of cmHSP70 to bind to membrane HSP70, indicating that both molecules may compete for the same extracellular epitope of HSP70 on the exosomes ( Figure 1A) .
We next validated this BLI protocol with urine samples from cancer patients (breast, lung, and ovary cancers, n = 8) and healthy donors (n = 5). The results found with this protocol ( Figure 1B) were confirmed by customized ELISA analysis ( Figure 1C ). The number of HSP70 exosomes was higher in all cancer patients compared with healthy donors, for whom hardly any HSP70 exosomes could be detected, as shown in Figure 1B (mean signal = 0.07 nm ± 0.02 vs mean signal = 0.018 nm ± 0.003, P < .001) and Figure 1C (3.5 ng/mL ± 1.7 vs 0.17 ng/mL ± 0.11, P = .004). These results were highlighted by the fact that the total number of exosomes quantified by NanoSight in urine samples was in fact higher in healthy donors than in cancer patients, with mean exosome concentrations of 261 x 10 9 particles/mL ± 86 (control subjects) vs 66 x 10 9 particles/mL ± 36 (patients) (P = .0016) ( Figure 1D ; Supplementary Figure 2 , available online).
HSP70 Exosomes Are Released From Tumor Cells
To study how HSP70 exosomes are specific markers of tumorderived exosomes, we started evaluating the release of exosomes in culture media from four cancer cell lines (HCT116 and SW480 human colon cancer, CT26 mouse colon carcinoma and B16F10 mouse melanoma), in the noncancerous mouse embryonic fibroblasts (MEFs) and primary cultures of colon intestinal epithelial cells (NCMs). First, to avoid any artifact related to the presence of other microvesicles potentially copurified with exosomes, we validated the expression of specific classical markers of exosomes in all samples such as Flotillin-1 and CD81 ( Figure 2A) . Next, to determine the presence of HSP70 in the membranes of exosomes, we used flow cytometry ( Figure 2B ), standard transmission electronic microscopy (Supplementary Figure 3A, available online), and our BLI protocol to capture HSP70 exosomes ( Figure 2C ). All these different techniques indicated that extracellular HSP70 was detectable only at the surface of exosomes derived from the cancer cell lines analyzed. We further validated that HSP70 exosomes were a general feature of cancer cells by analyzing a broader panel of cancer cells: prostate PC3, lymphoma EL4, cervix HeLa, and breast cancer MCF-7. They were compared with the following noncancerous cells: prostate PrEC cells, primary lymphocytes (PLs), uterine cells (PUCs), and breast epithelial cells (HMECs). As shown in Figure 2D , we found that all cancer cells released a high amount of HSP70 exosomes as compared with their normal counterparts, for which hardly any release of HSP70 exosomes could be detected.
Paralleling the analysis of membrane-bound HSP70 in the exosomes, we checked the expression of HSP70 in the plasma membrane of different cells by immunofluorescence and FACS analysis (Supplementary Figure 3 , B and C, and not shown). We observed that, as already reported, membrane-bound HSP70 was only detected in cancer but not in normal cells. This could explain why release of exosomes presenting HSP70 at their membranes may be a general feature of a cancer cells.
A8 Blocks the Ability of HSP70 to Associate With TLR2
Activation of MDSC by exosomes is mediated via the binding of extracellular HSP70 to TLR2 expressed on MDSC (17) . We therefore studied whether A8 could interfere with HSP70/TLR2 interaction. As shown in Figure 3A , HSP70 association to TLR2 was inhibited by A8 in a dose-dependent manner (from 0.3 µM article to 1.8 µM). A8 also blocked, in a dose-dependent manner, HSP70 chaperone activity as measured by a luciferase refolding assay. For instance, for a three-fold increase in the concentration of A8, we obtain a four-fold reduction in HSP70 chaperon activity (P = .006) ( Figure 3B ).
To further characterize these associations, we next immobilized A8 or TLR2 on the surface of the biosensor and determined their affinity constant (K D ) for HSP70. The K D of HSP70 for A8 and TLR2 was 2.2 nM and 33 nM, respectively (Figure 3, C and D), indicating that HSP70 displays a greater affinity for A8 than for TLR2. This could explain why A8 prevents the interaction between HSP70 and TLR2.
A8 Blocks the Ability of Tumor-Derived Exosomes to Activate MDSCs
The TLR2-dependent activation of MDSC by exosomes involves IL-6 release that triggers the activation of its receptor and the phosphorylation of STAT3 (27, 28) . Therefore, we evaluated the ability of A8 to prevent the activation of MDSCs by exosomes by determining IL-6 secretion and STAT3 phosphorylation status.
MSC2s were incubated in the presence or absence of TDEs (isolated from B16F10 cells) and/or A8. Supernatants were harvested and secreted IL-6 quantified by ELISA. As expected, we found that TDEs stimulate the secretion of IL-6 induced by MSC2s. Importantly, this IL-6 production was dose-dependently abrogated by A8 (ie, 81 pg/mL ± 19 vs 28 pg/mL ± 0.7 and 19 ± 1, P = .04 for a concentration of A8 of 8 µM and 16 µM, respectively) ( Figure 4A ). A8 provoked a similar blockage of IL-6 release induced by TDEs when, instead of MSC2, we used primary MDSC isolated from the spleen of mice (109.4 pg/mL ± 14 vs 5.26 pg/mL ± 3.9 in the presence of 16 µM A8, P = .012) ( Figure 4B ).
Then, we studied STAT3 phosphorylation kinetics by western blot in MSC2s induced by TDEs isolated from the supernatant of the four different cancer cell lines (B16F10, CT26, HCT116, or SW480) with or without A8. In the absence of TDEs, hardly any phosphorylation of STAT3 in MSC2s was observed, indicating little or no activation of STAT3 at basal level ( Figure 4C ), and that A8 does not have a direct effect (Supplementary Figure 4A , available online). In contrast, in the presence of TDE STAT3 phosphorylation was induced ( Figure 4C ). The addition of A8 in the culture medium inhibited the ability of TDEs to phosphorylate STAT3 in MSC2s. This effect was reproducible because this inhibitory effect was observed with exosomes isolated from four different cancer cells ( Figure 4C ). Further, a similar inhibitory effect of STAT3 phosphorylation by A8 was observed in primary MDSCs ( Figure 4D ). To confirm the role of A8 blocking the activation of MDSCs by TDEs, we analyzed other markers of MDSC activity, ie, IL-10 release and MDSCs' ability to induce the release of IFNγ by naive T-cells. As shown in Figure 4 , E and F, A8 blocked the ability of TDEs to induce IL-10 release on MDSC (108 pg/mL ± 11 vs 56 pg/mL ± 6.6, P = .049) and was able to rescue T-cell activation (IFNγ release: 1657 pg/mL ± 45 vs 115 pg/mL ± 54, P = .008).
To further prove that the inhibitory effect of A8 on MSC2 activation was because of its direct interaction with the extracellular domain of HSP70 at the exosomes surface, we tested the effect of A17, another peptide aptamer. We previously demonstrated that A17 binds to the ATP-binding domain of HSP70, immobilized on streptavidin sensor tips. Binding curves represent mean signal of triplicate measurements for each sample. Mann-Whitney: ***P < .001. C) Exosomes expressing HSP70 were determined by a customized enzyme-linked immunosorbent assay in urine samples from healthy individuals (n = 5) and cancer patients (breast, pulmonary and ovary, n = 8). Data are means and standard deviations of the nanovesicle concentrations (P = .004). D) Nanoparticle tracking analysis (NTA) to quantify total number of exosomes in the urine samples described above. Samples were diluted in PBS and analyzed using a NanoSight LM10 instrument. Data points are total numbers of exosomes (10 9 /mL). Error bars represent standard deviations, Mann-Whitney: **P = .0016. All statistical tests were two-sided.
article which is located in the intracellular N-terminal region of membrane-bound HSP70 (23) . As shown in Supplementary Figure 4B (available online), A17, in contrast to A8, did not interfere with the ability of tumor-derived exosomes to induce STAT3 phosphorylation in MSC2s.
We also checked by FACS whether A8, when incubated with tumor-derived exosomes, could affect the survival of MSC2s. As shown in Supplementary Figure 4C (available online), A8 alone or together with tumor-derived exosomes, did not induce any substantial cell death.
Altogether, these results demonstrate that A8, by its interaction with the extracellular domain of HSP70 in the tumorderived exosomes, blocks their ability to induce the activation of MDSCs through the STAT3-signaling pathway. Because it has 
Tumor-Bearing Mice Treated With A8 Develop an Anticancer Immune Response Involving MDSCs
To study the effect of A8 in vivo, we used two rodent cancer models: melanoma B16F10 and lymphoma EL4 tumors developed in C57BL/6 mice. We performed subcutaneous injection of cells or media as a control at day 0, and when tumor size reached about 0.9 mm 3 mice were treated i.p. with a control peptide aptamer (A0) or A8 every two days until the end of the experiment. When indicated, half of the mice received i.p. a single dose of cisplatin (5 mg/kg) or 5-fluorourcil (5FU, 25 mg/kg) for the B16F10 or EL4 models, respectively. At day 12 (B16F10) or 10 (EL4), we analyzed the percentage of MDSCs present in mice spleens (n = 6 mice per group) ( Figure 5A for the B16F10 model and Figure 5B for the EL4 model). In agreement with the literature (30), we found 2.5 % ± 0.9 of MDSC in the spleen of mice with no tumors (controls, n = 6 per group), whereas in tumor-bearing mice (and control-treated with an A0 aptamer that does not bind to HSP70) (23) we observed a four-to five-fold increase in the percentage of MDSC (compare 2.5 % ± 0.9 vs 12.9 % ± 1.2; Figure 5A ; or vs 14.3 ± 1.7; Figure 5B ; P = .02). Importantly, this increase was strongly decreased in tumor-bearing mice treated by A8, where we obtained values of 6 ± 0.7 ( Figure 5A ) or 5.3 % ± 0.3 ( Figure 5B , P = .02, n = 6 for each group). In tumor-bearing mice treated with cisplatin or 5FU alone, the percentage of MDSCs was 9 % ± 1 and 4.75 % ± 1.2, respectively, for the B16F10 an EL4 models, whereas in the spleen of tumor-bearing mice treated with both A8 and cisplatin or A8 and 5FU only barely 2.7 % ± 0.8 and 1.83 % ± 0.9 of MDSCs were found. Remarkably, these percentages were similar to that found in mice bearing no tumors. A8 not only decreased the number of MDSCs after cisplatin treatment but also, as expected, affected their activity as determined by phosphorylated STAT3 ( Figure 5A ).
In the two models, the decrease in MDSC induced by A8 was associated with tumor regression (eg, in the CDDP-and 5FU-treated mice, n = 6 mice/group, the mean tumor volume diminished from 1950 mm 3 ± 620 to 523 mm 3 ± 70, P = .049, for the B16F10 model; Figure 5C ; and from 1303 mm 3 ± 93 to 81 mm 3 ± 39, P = .0048, for the EL4 model; Figure 5D ) and with intratumor infiltration of immune cells, notably T cells (CD3 article abundantly infiltrated the tumor in A8-treated mice were skewed toward the cytotoxic phenotype as demonstrated by DHE, NOS2, pSTAT1, and Socs1 markers ( Figure 5F ). We then determined whether cisplatin or 5FU increased the amount of HSP70 exosomes, which could explain why their combination with A8 decreased MDSCs and increased the drugs' antitumor properties. We isolated total exosomes from both cultured B16F10 ( Figure 6A ) and blood of tumor-bearing mice ( Figure 6B ) by ultracentrifugation and quantified HSP70 exosomes by FACS and BLI, respectively. We found that the amount of HSP70 exosomes released by B16F10 cells strongly increased after cisplatin treatment (19 % ± 2.9 vs 69 ± 7, P = .04) ( Figure 6A ) and that the amount of HSP70 exosomes in the blood was much higher in cisplatin-treated mice (mean signal of 0.02 nm ± 0.01 vs 0.06 nm ± 0.01, P < .001) ( Figure 6B ). We tested whether this ability to increase the number of HSP70 exosomes was specific to cisplatin or could be extended to other anticancer drugs. As shown in Figure 6C , all drugs tested at toxic equivalent concentrations, to a greater (oxaliplatin, 5FU) or lesser (doxorubicin) extent, induce an increase in the amount of HSP70 exosomes. A dose-response release of HSP70 exosomes for cisplatin, 5FU, and doxorubicin is shown in Figure 6D . We observed for the three drugs that the amounts of HSP70 exosomes released increased with drug concentration, but only for concentrations inducing a relatively low amount of cell death. At higher doses inducing more than 40% cell death, the number of exosomes drastically decreased, suggesting that increased HSP70 exosome amount is not just because of cell death and release. For example, for 5FU concentrations of 3,12, 24, and 36 µM inducing a percentage of cell death of 4.8, 10.2, 30, and 43, respectively, we obtained a percentage of HSP70 exosomes released of 5.1, 12, 65, and only 6.6, respectively ( Figure 6D , left and right panels).
Discussion
In this study, we demonstrated that the peptide aptamer A8 tightly binds to extracellular membrane-bound HSP70 present in TDEs and that this association blocks the ability of exosomes to activate 
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MDSCs. We show in vivo the utility of associating A8 with a chemotherapeutic drug (cisplatin, 5-fluorouracil) in order to restore an efficient antitumoral immune response. Finally, we showed proof of principle that A8 can be used to quantify TDEs in human samples. The advantage of using A8 over antibodies targeting extracellular HSP70 such as cmHSP70 is that peptide aptamers are stable, soluble, easy to produce, and small (~11kDa) (25) . As cancer cells accumulate mutations, violate physiological laws, and acquire sets of hallmarks (31), they require a constitutively high level of chaperones like HSP70 for their survival/maintenance. Because only 10% of the total amount of intracellular HSP70 is expressed at the cytoplasmic membrane, this most likely explains why exosomes from normal cells are devoid of membrane-bound HSP70. Here, we have used a peptide aptamer, A8, targeting the extracellular domain of HSP70 on exosomes, blocking HSP70 association with the MDSC receptor TLR2 and thus MDSC activation. A8 also blocked MDSC proliferation, probably because of its ability to inhibit IL-6 production and pSTAT3, which can affect the expression of genes such as cyclin D, Mcl1, or Myc, reported to be involved in cell growth (32) . A8-induced reduction in the number of MDSCs in the spleens of tumor-bearing mice, which was particularly strong after cisplatin or 5FU treatment, could not be explained by a possible repositioning of MDSC, at least from the spleen toward the tumors, because tumor infiltration with MDSCs was very scarce in all mice, with no statistically significant differences among the groups (data not shown).
A8, by interfering with the immune suppressive functions of TDEs, may improve the efficacy of anticancer drugs. Indeed, we demonstrated that cisplatin or 5FU combined with A8 decreased tumor growth and favored the development of an anticancer immune response characterized notably by an important infiltration of cytotoxic M1-like macrophages. Although T-cells are the direct target of MDSCs, this macrophage infiltration can be explained by the reported cross-talk existing between MDSC/Tcells and macrophages (33) . Indeed, T-cells are the primary immune cells responsible for the A8 antitumor effect as demonstrated by the fact that: 1) in nude mice, the A8 antitumor effect is completely abolished (23) and 2) as shown in this work, the A8 effect directly involves MDSCs, whose main direct targets are T-cells. To determine which subset of T-cells is responsible for the A8 effect, we immunodepleted CD4+ or CD8+ cells by repetitive i.p. injection with specific neutralizing antibodies. Our results clearly show that whereas CD8 depletion inhibits A8 antitumor effect, CD4 depletion does not seem to have any notable effect (Supplementary Figure 7, available online) .
Interestingly, A8 biodistribution experiments, after systemic administration, demonstrate that the peptide localizes mainly in the tumor area (34) , likely because of the abundant expression of HSP70 in tumors. Considering the general role of HSP70 in different cancers and its induction by a large panel of anticancer agents, the anticancer immune approach proposed in this work involving inhibition of HSP70 exosomes might be extended to different cancer types with their respective chemotherapeutic setups. It is worth noting that neither our studies nor those done for the biodistribution of A8 indicated any evident toxicity in the mouse models, notably cardiac or hepatic.
Besides the rationale for a combination therapy, our results in human samples suggest that HSP70 exosomes could be used as a cancer biomarker (Supplementary Figure 8 , available online). The main advantage to quantifying tumor-derived exosomes compared with circulating tumor cells (CTCs) is that exosomes are found in large amounts compared with CTCs and that exosomes can be quantified both in blood and urine, as demonstrated here.
The main limitation of this study is the small number of patients analyzed. To confirm our results, we have just started a three-year prospective study with the anticancer Centre Georges-François Leclerc (Dijon, France) that will include 60 breast, ovary, and lung cancer patients and 20 healthy voluntary donors. In this prospective study and follow-up clinical trial, we will determine whether the presence of HSP70 exosomes is predictive of patient response to chemotherapy and whether its detection precedes that of CTCs (CellSearch) and the appearance of metastases (determined by medical imaging).
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